Search PubMed⌕ Search

Biomedical subjects

J A Springer

Publications and source records attributed to J A Springer.

27 records · Page 2Linked to original sources

Growth of environmental mastitis pathogens in various bedding materials.

The objective of the study was to determine whether, under controlled conditions, bedding materials vary in their ability to support growth of different environmental pathogens independent of the presence of feces, urine, or other contamination. Five sterilized bedding materials (fine hardwood chips, recycled dried manure, chopped newspaper, softwood sawdust, and chopped straw) and three bacterial species (Escherichia coli, Klebsiella pneumoniae, and Streptococcus uberis) were used for a total of 15 bedding/bacteria combinations, replicated in three trials. Samples were incubated at 37 degrees C, and bacterial counts were determined over 5 d. Rapid growth was seen in straw and recycled manure, some growth occurred in hardwood chips, and a rapid decline in bacterial counts was observed in paper and softwood sawdust. In general, K. pneumoniae and E. coli showed more rapid growth or less rapid decline than did S. uberis. These results demonstrate that clean, damp bedding may support bacterial growth and suggest that high bacterial counts under barn conditions are influenced by factors more complex than type of bedding used.

Animals↗

Subclinical mastitis of beef cows.

Two beef cow herds were investigated to determine the prevalence of subclinical mastitis and to determine whether it contributed to decreased weaning weight of calves nursed by affected cows. Quarter samples obtained about 30 days after calving were evaluated by the California mastitis test and by direct microscopic cell count. In 1 herd, a 92-cow confinement operation, 17 quarters of 12 cows were infected with Staphylococcus aureus, Streptococcus sp other than agalactiae, or Klebsiella sp. Mean 205-day adjusted weights were 203.9 kg and 218.2 kg for calves nursed by infected vs noninfected cows. In the other herd, a 75-cow range-pasture operation, 8 quarters of 8 cows were infected, all with S aureus. Mean 205-day adjusted weights were 162.5 kg and 174.6 kg for calves nursed by infected vs noninfected cows.

Animals↗

Protection of calves against fatal enteric colibacillosis by orally administered Escherichia coli K99-specific monoclonal antibody.

A monoclonal antibody (MCA) to enterotoxigenic Escherichia coli K99 antigen agglutinated K99+ enterotoxigenic E. coli strains B44 (O9:K30;K99;F41:H-) and B41 (O101:K99;F41:H-) grown at 37 degrees C but not at 18 degrees C. The MCA, which was characterized as immunoglobulin G1, reacted specifically with K99 antigen in an enzyme-linked immunosorbent assay and precipitated radiolabeled K99 antigen. A total of 45 colostrum-fed and colostrum-deprived calves were used in three separate trials to determine whether the orally administered K99-specific MCA would prevent diarrhea caused by strain B44. Twenty-eight calves were fed 1 ml of mouse ascitic fluid containing K99-specific MCA at 10 h of age and were orally challenged with strain B44 at 12 to 14 h of age. Control calves either received no placebo or were fed 1 ml of mouse ascitic fluid containing fibronectin-specific MCA at 10 h of age. There was no difference in the incidence of diarrhea between the two groups after challenge. However, the severity of diarrhea, as evaluated by the proportion of calves in each group that developed severe dehydration, the degree of clinical dehydration, the degree of clinical depression, the degree of weight loss, and the duration of diarrhea after challenge was significantly reduced in calves that received the K99-specific MCA. The mortality rate was also significantly lower (P less than 0.001) in the treated (29%) than in the control (82%) group. These results suggest that orally administered K99-specific MCA can prevent severe fatal enteric colibacillosis.

Animals↗

Protocols for the dominant lethal test, host-mediated assay, and in vivo cytogenetic test used in the food and drug administration's review of substances in the gras (generally recognized as safe) list.

Protocols are described for the dominant lethal and in vivo cytogenetics test in rats and the host-mediated assay, using Salmonella typhimurium and Saccharomyces cerevisiae in mice, as used by the Food and Drug Administration in its mutagenicity review of substances from the generally recognized as safe (GRAS) list. In addition proctolols are described for in vitro mutagenicity tests with S. typhimurium and S. cerevisiae and for statistical treatment for evaluation of data from dominant lethal tests.

Animals↗

Additional statistical evaluation and pharmacological considerations of hycanthone methanesulfonate-induced dominant lethality.

Investigations of the mutagenicity of hycanthone methanesulfonate (HCT) in mammals have led to varied results. To avoid ambiguous interpretation of significant results previously reported in two dominant-lethal studies of HCT a nested analysis of variance was performed on the number of corpora lutea per pregnant female, the number of implantations per pregnant female, average preimplantation losses, the number of dead implants per pregnant female, and the number of live implants. The analysis showed that variability among males and females was not responsible for the reported significant effects and consequently established the validity of the previous studies. Based on a comparison of the mammalian mutagenicity work performed utilizing hycanthone, pharmacokinetic factors are thought to be responsible for the differences seen; consideration of these factors in the future may lead to fewer false-negative results in mammalian systems.

Analysis of Variance↗

Statistical sampling approaches.

This article describes basic sampling principles and the application of statistical sampling techniques to specific problems encountered in the Food and Drug Administration (FDA). Concepts are emphasized, and theory is minimized. The basic principles of sampling from a normal and binomial population, including confidence interval calculation and sample size determination, are briefly reviewed. Stratified, random, systematic, and judgment sampling are explained. Operating characteristic curves for attribute (and perhaps variable) sampling for acceptance of lots are derived and applied to specific FDA problems. The advantages and disadvantages of single and multiple sampling plans and plans which address multiple classes of criteria such as major and minor defects are discussed. Sampling schedules such as MIL-STD-105D and Canada's Government Specifications Board CGSB-105-GP-1 are reviewed to familiarize readers with the principles involved in these plans and to give them an idea of how they could be applied to FDA problems.

Chemistry Techniques, Analytical↗